Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab + RVd in Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2012
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by SWOG Cancer Research Network. Started Nov 2012; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01668719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01668719.